Prognostic utility of inflammation biomarkers in a PDAC trial involving the human anti-CTGF antibody pamrevlumab.

Mark D. Sternlicht,Dongxia Li,Viet-Tam L. Nguyen,Mairead Carney,Duo Zhou,Kenneth E. Lipson,Elias Kouchakji,Vincent J. Picozzi,Ewa Carrier,Todd W. Seeley

Prognostic utility of inflammation biomarkers in a PDAC trial involving the human anti-CTGF antibody pamrevlumab.

2020

Mark D. Sternlicht
Dongxia Li
Viet-Tam L. Nguyen
Mairead Carney
Duo Zhou
Kenneth E. Lipson
Elias Kouchakji
Vincent J. Picozzi
Ewa Carrier
Todd W. Seeley

752Background: Pancreatic ductal adenocarcinomas (PDAC) often exhibit desmoplasia, elevated CTGF (connective tissue growth factor) expression and inflammation. The influence of inflammation on pati...

Keywords:

Inflammation
Antibody
Cancer research
Medicine
CTGF
Biomarker (medicine)
Pathology
pancreatic ductal
Connective tissue
inflammation biomarkers
Desmoplasia
Growth factor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations